Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 356

1.

Stability and Priority of Symptoms and Symptom Clusters Among Allogeneic HSCT Patients Within a 5-Year Longitudinal Study.

Esser P, Kuba K, Scherwath A, Johansen C, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander AR, Kröger N, Götze H, Mehnert A.

J Pain Symptom Manage. 2017 Oct;54(4):493-500. doi: 10.1016/j.jpainsymman.2017.07.012. Epub 2017 Jul 13.

PMID:
28711754
2.

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.

Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schäfer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A.

J Hematol Oncol. 2017 Jun 24;10(1):130. doi: 10.1186/s13045-017-0498-8.

3.

Investigating the temporal course, relevance and risk factors of fatigue over 5 years: a prospective study among patients receiving allogeneic HSCT.

Esser P, Kuba K, Mehnert A, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander AR, Kröger N, Schilling G, Götze H, Scherwath A.

Bone Marrow Transplant. 2017 May;52(5):753-758. doi: 10.1038/bmt.2016.344. Epub 2017 Jan 23.

PMID:
28112750
4.

β-MSCs: successful fusion of MSCs with β-cells results in a β-cell like phenotype.

Azizi Z, Lange C, Paroni F, Ardestani A, Meyer A, Wu Y, Zander AR, Westenfelder C, Maedler K.

Oncotarget. 2016 Aug 2;7(31):48963-48977. doi: 10.18632/oncotarget.10214.

5.

Mesenchymal Stromal/Stem Cells Do Not Ameliorate Experimental Autoimmune Encephalomyelitis and Are Not Detectable in the Central Nervous System of Transplanted Mice.

Abramowski P, Krasemann S, Ernst T, Lange C, Ittrich H, Schweizer M, Zander AR, Martin R, Fehse B.

Stem Cells Dev. 2016 Aug 1;25(15):1134-48. doi: 10.1089/scd.2016.0020. Epub 2016 Jul 13.

PMID:
27250994
6.

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria.

Ayuk F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander AR, Kröger N.

Ann Hematol. 2015 Oct;94(10):1727-32. doi: 10.1007/s00277-015-2452-6. Epub 2015 Jul 24.

PMID:
26204824
7.

Immunomodulatory effects of the ether phospholipid edelfosine in experimental autoimmune encephalomyelitis.

Abramowski P, Steinbach K, Zander AR, Martin R.

J Neuroimmunol. 2014 Sep 15;274(1-2):111-24. doi: 10.1016/j.jneuroim.2014.07.007. Epub 2014 Jul 21.

8.

Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines.

Valdez BC, Zander AR, Song G, Murray D, Nieto Y, Li Y, Champlin RE, Andersson BS.

Blood Cancer J. 2014 Jan 10;4:e171. doi: 10.1038/bcj.2013.69.

9.

Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation.

Ayuk F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander AR, Kröger N.

Ann Hematol. 2014 May;93(5):855-61. doi: 10.1007/s00277-013-1957-0. Epub 2013 Nov 19.

PMID:
24248672
10.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.

Oyekunle A, Zander AR, Binder M, Ayuk F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N.

Ann Hematol. 2013 Apr;92(4):487-96. doi: 10.1007/s00277-012-1650-8. Epub 2012 Dec 19.

PMID:
23250623
11.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

Kröger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander AR.

Biol Blood Marrow Transplant. 2013 Mar;19(3):398-404. doi: 10.1016/j.bbmt.2012.10.008. Epub 2012 Oct 16.

12.

Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study.

Scherwath A, Schirmer L, Kruse M, Ernst G, Eder M, Dinkel A, Kunze S, Balck F, Bornhäuser M, Ehninger G, Dolan K, Gramatzki M, Kolb HJ, Heußner P, Wilhelm H, Beelen DW, Schulz-Kindermann F, Zander AR, Koch U, Mehnert A.

Psychooncology. 2013 Jul;22(7):1509-16. doi: 10.1002/pon.3159. Epub 2012 Sep 4.

PMID:
22945857
13.

Evaluation of BM cytomorphology after allo-SCT in patients with MDS.

Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuk F, Schafhausen P, Zander AR, Bokemeyer C, Kröger N, Bacher U.

Bone Marrow Transplant. 2013 Mar;48(3):465-6. doi: 10.1038/bmt.2012.161. Epub 2012 Sep 3. No abstract available.

PMID:
22941378
14.

Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.

Klyuchnikov E, Holler E, Bornhäuser M, Kobbe G, Nagler A, Shimoni A, Könecke C, Wolschke C, Bacher U, Zander AR, Kröger N.

Br J Haematol. 2012 Oct;159(2):172-81. doi: 10.1111/bjh.12013. Epub 2012 Aug 22.

PMID:
22909192
15.

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.

Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger KH, Burchert A, Stübig T, Wolschke C, Ayuk F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander AR.

Bone Marrow Transplant. 2013 Mar;48(3):403-7. doi: 10.1038/bmt.2012.142. Epub 2012 Aug 6.

PMID:
22863722
16.

Role of interleukin 16 in multiple myeloma.

Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander AR, Marx AH, Uhlig R, Zustin J, Bokemeyer C, Kröger N.

J Natl Cancer Inst. 2012 Jul 3;104(13):1005-20. doi: 10.1093/jnci/djs257. Epub 2012 Jun 28.

PMID:
22745469
17.

Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.

Finke J, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Bertz H, Grishina O, Socié G; ATG-Fresenius Trial Group.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1716-26. doi: 10.1016/j.bbmt.2012.06.001. Epub 2012 Jun 17.

18.

Evaluation of BM cytomorphology after allo-SCT in patients with AML.

Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuk F, Schafhausen P, Zander AR, Bokemeyer C, Kröger N, Bacher U.

Bone Marrow Transplant. 2012 Dec;47(12):1538-44. doi: 10.1038/bmt.2012.70. Epub 2012 Apr 30.

PMID:
22543745
19.

Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, Arnold R, Greinix H, Cornelissen JJ, Jackson GH, Craddock C, Bunjes DW, Ganser A, Russell NH, Kyrcz-Krzemien S, Rocha V, Mohty M.

Biol Blood Marrow Transplant. 2012 Sep;18(9):1422-9. doi: 10.1016/j.bbmt.2012.02.013. Epub 2012 Mar 20.

20.

Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.

Alchalby H, Yunus DR, Zabelina T, Kobbe G, Holler E, Bornhäuser M, Schwerdtfeger R, Bethge W, Kvasnicka HM, Büsche G, Ayuk F, Bacher U, Zander AR, Kröger N.

Br J Haematol. 2012 Apr;157(1):75-85. doi: 10.1111/j.1365-2141.2011.09009.x. Epub 2012 Jan 27.

PMID:
22280409
21.

Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.

Casper J, Holowiecki J, Trenschel R, Wandt H, Schaefer-Eckart K, Ruutu T, Volin L, Einsele H, Stuhler G, Uharek L, Blau I, Bornhaeuser M, Zander AR, Larsson K, Markiewicz M, Giebel S, Kruzel T, Mylius HA, Baumgart J, Pichlmeier U, Freund M, Beelen DW.

Bone Marrow Transplant. 2012 Sep;47(9):1171-7. doi: 10.1038/bmt.2011.242. Epub 2011 Dec 12.

PMID:
22158386
22.

Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.

Oyekunle A, Haferlach T, Kröger N, Klyuchnikov E, Zander AR, Schnittger S, Bacher U.

Adv Hematol. 2011;2011:154745. doi: 10.1155/2011/154745. Epub 2011 Nov 10.

23.

Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.

Langebrake C, Bernhardt F, Baehr M, Kröger N, Zander AR.

Int J Clin Pharm. 2011 Dec;33(6):918-24. doi: 10.1007/s11096-011-9568-0. Epub 2011 Sep 29. Review.

PMID:
21960151
24.

Unusual course of myelodysplastic syndrome with presumed familial origin.

Bacher U, Ocheni S, Schafhausen P, Oyekunle A, Dierlamm J, Zander AR, Bokemeyer C, Haferlach T, Kröger N.

Acta Haematol. 2011;126(4):234-7. doi: 10.1159/000330529. Epub 2011 Sep 22. No abstract available.

PMID:
21952642
25.

Mesenchymal stromal cells: main factor or helper in regenerative medicine?

Zander AR, Lange C, Westenfelder C.

Kidney Int Suppl (2011). 2011 Sep;1(3):74-76. Review.

26.

High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T.

J Clin Oncol. 2011 Aug 20;29(24):3214-23. doi: 10.1200/JCO.2010.32.5910. Epub 2011 Jul 18.

27.

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.

Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, Holowiecki J, Giebel S, Markiewicz M, Uharek L, Blau IW, Kienast J, Stelljes M, Larsson K, Zander AR, Gramatzki M, Repp R, Einsele H, Stuhler G, Baumgart J, Mylius HA, Pichlmeier U, Freund M, Casper J.

Haematologica. 2011 Sep;96(9):1344-50. doi: 10.3324/haematol.2011.043810. Epub 2011 Jun 9.

28.

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.

Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübig T, Hilde-brandt Y, Atanackovic D, Alchalby H, Ayuk F, Zander AR, Bacher U, Eiermann T.

Leukemia. 2011 Oct;25(10):1657-61. doi: 10.1038/leu.2011.138. Epub 2011 Jun 7. No abstract available.

PMID:
21647155
29.

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.

Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, Lajmi N, Zander AR, Marx AH, Bokemeyer C, Kröger N.

Haematologica. 2011 Oct;96(10):1512-20. doi: 10.3324/haematol.2010.036814. Epub 2011 May 23.

30.

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.

Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Finke J; ATG-Fresenius Trial Group.

Blood. 2011 Jun 9;117(23):6375-82. doi: 10.1182/blood-2011-01-329821. Epub 2011 Apr 5.

PMID:
21467544
31.

Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Oyekunle A, Klyuchnikov E, Ocheni S, Kröger N, Zander AR, Baccarani M, Bacher U.

Acta Haematol. 2011;126(1):30-9. doi: 10.1159/000323662. Epub 2011 Mar 17. Review.

32.

Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.

Alchalby H, Lioznov M, Fritzsche-Friedland U, Badbaran A, Zabelina T, Bacher U, Stübig T, Ayuk FA, Zander AR, Kröger N.

Bone Marrow Transplant. 2012 Jan;47(1):143-5. doi: 10.1038/bmt.2011.17. Epub 2011 Feb 28. No abstract available.

PMID:
21358677
33.

Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia.

Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H, Ehninger G, Steckel NK, Zander AR, Schwerdtfeger R, Buchholz S, Kolb HJ, Volin L, Fauser A, Polge E, Schmid C, Mohty M, Rocha V.

Leukemia. 2011 May;25(5):808-13. doi: 10.1038/leu.2011.13. Epub 2011 Feb 22.

PMID:
21339758
34.

Radiation rescue: mesenchymal stromal cells protect from lethal irradiation.

Lange C, Brunswig-Spickenheier B, Cappallo-Obermann H, Eggert K, Gehling UM, Rudolph C, Schlegelberger B, Cornils K, Zustin J, Spiess AN, Zander AR.

PLoS One. 2011 Jan 5;6(1):e14486. doi: 10.1371/journal.pone.0014486.

35.

Second allogeneic stem cell transplantation in a patient with hypoplastic myelodysplastic syndrome following a primary diagnosis of aplastic anaemia.

Ocheni S, Oyekunle A, Kröger N, Ayuk F, Klyuchnikov E, Arps S, Held K, Zabelina T, Adjallé R, Wolschke C, Zander AR, Bacher U.

Acta Haematol. 2011;125(3):175-8. doi: 10.1159/000322609. Epub 2010 Dec 30. No abstract available.

PMID:
21196720
36.

Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.

Lellek H, Waldenmaier D, Dahlke J, Ayuk FA, Wolschke C, Kröger N, Zander AR.

Mycoses. 2011 Jan;54 Suppl 1:39-44. doi: 10.1111/j.1439-0507.2010.01985.x.

PMID:
21126271
37.

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.

Klyuchnikov E, Bacher U, Kröger N, Kazantsev I, Zabelina T, Ayuk F, Zander AR.

Adv Hematol. 2011;2011:974658. doi: 10.1155/2011/974658. Epub 2010 Oct 26.

38.

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N.

Bone Marrow Transplant. 2011 Aug;46(8):1045-52. doi: 10.1038/bmt.2010.249. Epub 2010 Oct 25.

PMID:
20972470
39.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.

Wiedemann B, Klyuchnikov E, Kröger N, Zabelina T, Stahl T, Zeschke S, Badbaran A, Ayuk F, Alchalby H, Wolschke C, Bokemeyer C, Fehse B, Zander AR, Bacher U.

Exp Hematol. 2010 Dec;38(12):1261-71. doi: 10.1016/j.exphem.2010.08.006. Epub 2010 Sep 17.

PMID:
20851159
40.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.

Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S, Schafhausen P, Schultz W, Asenova S, Smirnova A, Wolschke C, Ayuk F, Zander AR, Fehse B, Bacher U.

Leuk Lymphoma. 2010 Oct;51(10):1837-43. doi: 10.3109/10428194.2010.508822.

PMID:
20849383
41.

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.

Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, Meyer S, Bartels K, Zander AR, Bokemeyer C, Kröger N, Atanackovic D.

Exp Hematol. 2010 Oct;38(10):860-7. doi: 10.1016/j.exphem.2010.06.012. Epub 2010 Jul 7.

PMID:
20619313
42.

Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny.

Cavattoni I, Ayuk F, Zander AR, Zabelina T, Bacher A, Cayroglu E, Knospe V, Illies T, Aepfelbacher M, Richard G, Kröger N, Bacher U.

Leuk Lymphoma. 2010 Aug;51(8):1530-5. doi: 10.3109/10428194.2010.494260.

PMID:
20578813
43.

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.

Shimoni A, Hardan I, Ayuk F, Schilling G, Atanackovic D, Zeller W, Yerushalmi R, Zander AR, Kroger N, Nagler A.

Cancer. 2010 Aug 1;116(15):3621-30. doi: 10.1002/cncr.25228.

44.

Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia.

Klyuchnikov E, Asenova S, Kern W, Kilinc G, Ayuk F, Wiedemann B, Lioznov M, Freiberger P, Zalyalov Y, Zander AR, Kröger N, Bacher U.

Leuk Lymphoma. 2010 Aug;51(8):1450-63. doi: 10.3109/10428194.2010.496015.

PMID:
20557144
45.

Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.

Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, Wandt H, Schäfer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander AR, Kröger N, Hilgendorf I, Baumgart J, Mylius HA, Pichlmeier U, Freund M.

J Clin Oncol. 2010 Jul 10;28(20):3344-51. doi: 10.1200/JCO.2009.23.3429. Epub 2010 May 24. Erratum in: J Clin Oncol. 2010 Aug 10;28(23):3797.

PMID:
20498405
46.

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.

Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, Bornhäuser M, Thiede C, Baurmann H, Bethge W, Hildebrandt Y, Bacher U, Fehse B, Zander AR, Kröger N.

Blood. 2010 Nov 4;116(18):3572-81. doi: 10.1182/blood-2009-12-260588. Epub 2010 May 20.

PMID:
20489052
47.

Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission.

Gorin NC, Labopin M, Reiffers J, Milpied N, Blaise D, Witz F, de Witte T, Meloni G, Attal M, Bernal T, Rocha V; Acute Leukemia Working Party, European Cooperative Group for Blood and Marrow Transplantation.

Blood. 2010 Oct 28;116(17):3157-62. doi: 10.1182/blood-2009-11-252197. Epub 2010 May 17.

PMID:
20479285
48.

Limited immune-modulating activity of porcine mesenchymal stromal cells abolishes their protective efficacy in acute kidney injury.

Brunswig-Spickenheier B, Boche J, Westenfelder C, Peimann F, Gruber AD, Jaquet K, Krause K, Zustin J, Zander AR, Lange C.

Stem Cells Dev. 2010 May;19(5):719-29. doi: 10.1089/scd.2009.0494.

PMID:
20143956
49.

Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT.

Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander AR, Kröger N.

Bone Marrow Transplant. 2010 Sep;45(9):1404-7. doi: 10.1038/bmt.2009.367. Epub 2010 Jan 11.

PMID:
20062088
50.

Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.

Bacher U, Haferlach C, Kröger N, Schnittger S, Kern W, Wiedemann B, Zander AR, Haferlach T.

Biol Blood Marrow Transplant. 2010 Jan;16(1):1-11. doi: 10.1016/j.bbmt.2009.08.007. Epub 2009 Sep 30. Review.

Supplemental Content

Loading ...
Support Center